All In Biotech

Drug Trial Radar · NCT07672223

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Open-Label Study of SYS6010 in Combination With Anti-PD-(L)-1 Monoclonal Antibody Versus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy for Patients With Completely Resected Stage II-IIIB NSCLC Who Have No Actionable Genomic Alterations and Not Achieved a Major Pathological Response.

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Sep 30, 2029

Study completion Nov 30, 2031

Sponsor

Sponsor type
Industry
First posted
Jun 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • SYS6010Drug

    SYS6010

  • EnlonstobartDrug

    Enlonstobart

  • TislelizumabDrug

    administered via Intravenous (IV) injection

  • Toripalimab ±+platinum-based doublet chemotherapyDrug

    Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;

  • DurvalumabDrug

    Durvalumab

  • PembrolizumabDrug

    Pembrolizumab

  • NivolumabDrug

    Nivolumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) assessed by the independent review committee (IRC)Time frame: Up to approximately 60 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.